Clinical efficacy of CyberKnife radiotherapy for locally advanced pancreatic carcinoma
Song Yongchun, Yuan Zhiyong, Li Fengtong, Dong Yang, Zhuang Hongqing, Wang Jingsheng, Chen Huaming, Wang Ping
Department of Radiation Oncology and CyberKnife Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin Key Laboratory of Cancer Prevention and Therapy,National Clinical Research Center for Cancer, Tianjin 300060, China
Abstract：Objective To assess the efficacy and safety of CyberKnife radiotherapy in the treatment of locally advanced pancreatic carcinoma. Methods The data of 59 patients with locally advanced pancreatic carcinoma who were treated with CyberKnife radiotherapy from 2006 to 2014 were retrospectively analyzed. The tumor volume ranged from 13.0 cm3 to 125.1 cm3 with a median value of 27.1 cm3. A dose of 35-50 Gy (median value=45 Gy) in 3-8 fractions (median value=5 fractions) was prescribed. The tumor progression was evaluated based on computed tomography. The overall survival (OS) and local progression-free survival (LPFS) rates were calculated using the Kaplan-Meier method. Results The 1-and 2-year sample sizes were 26 and 17, respectively. The 1-and 2-year OS rates were 54% and 35%, respectively, while the 1-and 2-year LPFS rates were 91% and 70%, respectively. The median OS and LPFS times were 12.5 and 10.9 months, respectively. The overall incidence of grade 1-2 acute and late gastrointestinal toxicity was 61%. One patient with grade 3 late gastrointestinal toxicity had incomplete intestinal obstruction. Conclusions CyberKnife radiotherapy can achieve excellent treatment outcomes and mild complications in the treatment of locally advanced pancreatic carcinoma.
Song Yongchun,Yuan Zhiyong,Li Fengtong et al. Clinical efficacy of CyberKnife radiotherapy for locally advanced pancreatic carcinoma[J]. Chinese Journal of Radiation Oncology, 2015, 24(4): 392-394.
[1] Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J].CA Cancer J Clin,2010,60(5):277-300.DOI:10.3322/caac.20073. [2] Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 genestatus of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer[J]. J Clin Oncol,2009,27(11):1806-1813.DOI:10.1200/JCO.2008.17.7188. [3] Chang BK, Timmerman RD. Stereotactic body radiation therapy:a comprehensive review[J]. Am J Clin Oncol,2007, 30(6):637-644. [4] Nuyttens JJ, van de Pol M. The CyberKnife radiosurgery system for lung cancer[J]. Exp Rev Med Dev,2012,9(5):465-475.DOI:10.1586/erd.12.35. [5] Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreaticadenocarcinoma[J].JAMA,2008,299(9):1019-1026.DOI:10.1001/jama.299.9.1019. [6] Koong AC, Le QT, Ho A, et al. Phase Ⅰ study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer[J]. Int J Radiat Oncol Biol Phys,2004,58(4):1017-1021. [7] Schellenberg D, Kim J, Christman-Skieller C, et al. Single fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer[J]. Int J Radiat Oncol Biol Phys,2011,81(1):181-188.DOI:10.1016/j.ijrobp.2010.05.006. [8] Hoyer M,Roed H,Sengelov L,et al. Phase-Ⅱ study on stereotactic radiotherapy of locally advanced pancreatic carcinoma[J]. Radiother Oncol,2005,76(1):48-53.
2015, Vol. 24 
